Concepedia

Publication | Open Access

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

DOIFull Paper Access

639

Citations

0

References

2019

Year

Thomas Yau, J.W. Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, Kwang‐Hyub Han, James J. Harding, Philippe Merle,
Annals of Oncology

No additional data available for this publication yet. Check back later!